VolitionRx Limited (VNRX)
| Market Cap | 70.54M |
| Revenue (ttm) | 1.31M |
| Net Income (ttm) | -24.02M |
| Shares Out | 103.02M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 121,375 |
| Open | 0.6600 |
| Previous Close | 0.6677 |
| Day's Range | 0.6600 - 0.7100 |
| 52-Week Range | 0.3951 - 0.9400 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 3.88 (+466.67%) |
| Earnings Date | Aug 13, 2025 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived D... [Read more]
Financial Performance
In 2024, VolitionRx's revenue was $1.23 million, an increase of 59.10% compared to the previous year's $775,302. Losses were -$26.97 million, -23.65% less than in 2023.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price target is $3.88, which is an increase of 466.67% from the latest price.
News
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
HENDERSON, Nev. , July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleo...
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev. , June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epige...
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q®...
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev. , May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today an...
VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript
VolitionRX Limited (NYSE:VNRX) Q1 2025 Earnings Conference Call May 16, 2025 8:30 AM ET Company Participants Louise Batchelor – Chief Marketing and Communications Officer Terig Hughes – Chief Financi...
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev.
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
HENDERSON, Nev. , May 7, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that Chief Commercial Officer, Gael Forterre,...
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
HENDERSON, Nev. , April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive O...
VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript
VolitionRx Limited (NYSE:VNRX) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Cameron Reynolds - President...
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE A...
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how ...
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on W...
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PR...
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev.
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICA...
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev. , March 20,...
Volition Proudly Sponsors the 44th ISICEM Congress
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 HENDERSON, Nev. , March 17, 2025 /PRNewswire/ --...
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
HENDERSON, Nev. , March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test...
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Published study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening. The study is expected to be completed by the end of 2025 HENDERSON, Nev.
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
Nu.Q® Discover tools provide drug developers and scientists with a range of rapid epigenetic profiling assays across pre-clinical and clinical development pathways from discovery to market ready HENDE...
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM Representatives will also be available at exhibition booth #2943 HEND...
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies HENDERSON, Nev. , Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN...
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
HENDERSON, Nev. , Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Fri...
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
HENDERSON, Nev. , Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which sh...